BioWorld

June 11, 2007

Regeneron Completes Rolling BLA For IL-1 Trap In CAPS

Hoping to introduce the first marketed product for a group of rare chronic inflammatory conditions, Regeneron Pharmaceuticals Inc. completed a rolling biologics license application for its interleukin-1 (IL-1) Trap. (BioWorld Today) Read More

Auxilium Stock Sale: $49.9M To Boost Enzyme Products

Biotech vs. Big Accounting: New SOX rules may help

Acorda Raises $67 Million For Second Fampridine-SR Phase III

NewCo News: Viamet Gets $4 Million Series A For Targeting Metalloenzymes

Other News To Note

Clinic Roundup

Appointments And Advancements

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 13, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Science in 2025: the best of the rest

BioWorld Science

A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...